A phase 1/11 study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy
1997

Study of KU-2285 with Intraoperative Radiotherapy

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): Y Shibamoto, G Ohshio, R Hosotani, Y Nishimura, T Manabe, M Imamura, M Abel

Primary Institution: Kyoto University

Hypothesis

Does the hypoxic cell radiosensitizer KU-2285 improve outcomes when combined with intraoperative radiotherapy (IORT) for patients with unresectable tumors?

Conclusion

The study found that KU-2285 combined with IORT showed encouraging results in terms of survival and local control for patients with unresectable pancreatic cancer.

Supporting Evidence

  • Patients treated with KU-2285 had a median survival time of 11 months compared to 8 months for historical controls.
  • The 1-year local control rate for patients receiving KU-2285 was 50%, compared to 28% for controls.
  • No drug-related toxicity was observed in any patients.

Takeaway

Doctors tested a new drug called KU-2285 to see if it helps patients with hard-to-treat tumors when used with special radiation therapy, and it seemed to work well.

Methodology

Patients with unresectable tumors received KU-2285 before IORT, and their outcomes were compared to historical controls.

Limitations

The study had a small sample size and was not a formal phase I trial.

Participant Demographics

30 patients, 21 males and 9 females, median age 59 years, with 23 having pancreatic cancer and 5 having osteosarcoma.

Statistical Information

P-Value

0.26 for survival, 0.10 for local control

Statistical Significance

p=0.26 for survival, p=0.10 for local control

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication